RALES Score (Spironolactone Benefit Predictor)
Clinical evidence and safety review
Enter the patient's findings to review key RALES trial characteristics and initial MRA safety flags. This is not a validated individual benefit score.
Clinical context
The Randomized Aldactone Evaluation Study (RALES) tested spironolactone in patients with severe heart failure and LVEF ≤35%, generally NYHA class III–IV, receiving background therapy available at the time.
Among 1,663 participants, spironolactone was associated with a relative risk of death of 0.70 versus placebo (30% relative reduction) over a mean follow-up of approximately 24 months. Hospitalization for worsening heart failure was reduced by 35% relatively.
What this tool does—and does not do
- Summarizes whether selected inputs resemble key RALES trial characteristics.
- Flags creatinine and potassium values relevant to trial exclusion and MRA initiation safety.
- Does not calculate a validated RALES score, individualized treatment effect, absolute risk reduction, or NNT.
- Does not replace eGFR assessment, medication review, potassium/renal monitoring, or clinical judgment.
Key safety considerations
The 2022 AHA/ACC/HFSA guideline recommends an MRA for appropriate patients with symptomatic HFrEF when eGFR is >30 mL/min/1.73 m² and serum potassium is <5.0 mmol/L, with careful ongoing monitoring. Serum creatinine alone cannot establish the eGFR threshold.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.